AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02789813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once oral administration of 500mg before exposure therapy.
Trial: NCT03390179
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesure of the glucose concentration
Trial: NCT03615807
Drug: Antibiotic duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic duration according to the study arms
Trial: NCT00711048
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, single dose
Trial: NCT00711048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, single dose
Trial: NCT01113320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
Trial: NCT01530178
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04551898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BGB-DXP593 administered as specified in the treatment arm
Trial: NCT00973479
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Trial: NCT04012827
Drug: Apatinib Mesylate, doxorubicin, ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
Trial: NCT00589953
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
Trial: NCT00563953
Drug: Liposomal pegylated doxorubicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Trial: NCT03665766
Drug: Cycloserine,Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01000298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid placebo medication given twice per day for 7 days
Trial: NCT00003799
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003799
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01631201
Drug: Azithromycin 1 gram
RxNorm normalized name: azithromycin 1 gram ORAL PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Azithromycin 1 gram to be administered on Day 1.
Trial: NCT00141648
Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
Trial: NCT00879034
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
Trial: NCT00879034
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
Trial: NCT00973024
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
Trial: NCT01208324
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01208324
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
Trial: NCT01970176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Trial: NCT00570778
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Trial: NCT02014506
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV on day -3 and -2
Trial: NCT00711594
Drug: BIBW 2992 MA2 40mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Trial: NCT00711594
Drug: BIBW 2992 MA2 50mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Trial: NCT00711594
Drug: BIBW 2992 MA2 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Trial: NCT00711594
Drug: BIBW 2992 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
Trial: NCT02933879
Drug: NVXT topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment
Trial: NCT02933879
Drug: Placebo (Vehicle) Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Vehicle) Topical
Trial: NCT00232999
Drug: Nebulized IVX-0142
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Placebo 1 capsule x 3 daily until progression
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03637361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00438360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Trial: NCT01719458
Drug: (S,S)-[11C]MRB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radioligand
Trial: NCT02807389
Drug: MSC Fistula Plug
RxNorm normalized name: Cassia fistula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
Trial: NCT04539613
Drug: HPFSH & HMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . Various gonadotropin preparations
Trial: NCT01231334
Drug: Clindamycin/benzoyl peroxide plus Adapalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
Trial: NCT00039754
Drug: Holmium-166-DOTMP
RxNorm normalized name: holmium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01627054
Drug: AT7519M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
Trial: NCT03617081
Drug: NNC0113-2023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
Trial: NCT03617081
Drug: Placebo (NNC0113-2023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0174-0833 matched placebo orally.
Trial: NCT00641407
Drug: NPL insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 10 IU bedtime and then titration
Trial: NCT00384800
Drug: Thalidomide(THADO), Tegafur/Uracil(UFUR)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02912234
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose clarithromycin and single-dose Apixaban
Trial: NCT00372619
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally or IT age based dosage
Trial: NCT00405392
Drug: Ibandronate (SB743830HD)
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04325295
Drug: Recombinant FSH (rFSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
Trial: NCT02767869
Drug: Banaba
RxNorm normalized name: BANABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
Trial: NCT02767869
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
Trial: NCT04301934
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Trial: NCT03396497
Drug: LYC-55716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
Trial: NCT01901614
Drug: Topical Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00355862
Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: center specific therapeutic regimen without mTOR inhibition
Trial: NCT02191878
Drug: TKM-080301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKM-080301 intravenous infusion
Trial: NCT02742233
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment
Trial: NCT02517996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
Trial: NCT04128163
Drug: QL1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Trial: NCT02526953
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Trial: NCT02526953
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Trial: NCT00149799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
Trial: NCT01744067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules 3 times a day (oral administration)
Trial: NCT04428255
Drug: HBM9161 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Trial: NCT04428255
Drug: HBM9161 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Trial: NCT04428255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Trial: NCT00932438
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks
Trial: NCT02833584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mg x 1 tablets according to patient's body weight
Trial: NCT01095991
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet bd,
Trial: NCT00197418
Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04128163
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Trial: NCT01455922
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 is exenatide in DUROS
Trial: NCT01831466
Drug: placebo ointment (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ointment (vehicle) BID (twice daily) for 12 weeks
Trial: NCT01831466
Drug: placebo ointment (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ointment (vehicle) QD (once daily) for 12 weeks
Trial: NCT00482235
Drug: MK0359
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02291783
Drug: HTL0009936
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02291783
Drug: HTL0009936 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT04442633
Drug: Glutamine Cap/Tab
RxNorm normalized name: GLUTAMINE CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine Capsules: One capsule three times daily on an empty stomach for one month
Trial: NCT04442633
Drug: Kenacort in orabase
RxNorm normalized name: ORABASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
Trial: NCT00434993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
Trial: NCT02551380
Drug: FOLINORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
Trial: NCT03102515
Drug: CIC
RxNorm normalized name: BaciCap
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02935790
Drug: ACY-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT00192764
Drug: high-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06291337
Drug: Inhibition of Sweet Taste by Ibuprofen Oral Rinses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Trial: NCT06291337
Drug: Inhibition of Sweet Taste by Naproxen Oral Rinses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Trial: NCT01503346
Drug: DaHuang GanTsao Tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
Trial: NCT03657784
Drug: P03277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
Trial: NCT03727022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Trial: NCT03727022
Drug: SM04690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Trial: NCT02504931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
Trial: NCT02469987
Drug: MYL-1402O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
Trial: NCT00073411
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03581149
Drug: 2L polyethylene glycol/ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Trial: NCT00559104
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used in Both Arms
Trial: NCT03154515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02515799
Drug: Tacholiquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Tacholiquine ®1% - 5ml
Trial: NCT01780844
Drug: ASKP1240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00479570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02263326
Drug: Continue current antiretroviral regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue current DHHS recommended or alternative three-drug antiretroviral regimen
Trial: NCT00368745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
Trial: NCT01212887
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01722526
Drug: Recombinant human acid sphingomyelinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously every 2 weeks for 26 weeks
Trial: NCT00506168
Drug: Irinotecan, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03691337
Drug: Marcaine 0.25 % Injectable Solution
RxNorm normalized name: Marcaine 0.25 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca block with volume 0.11 mL x subject height